EL7.AI
StocksUpdated•Originally published 20 July 2026•Updated 21 July 2026•
2 min read

BMO Capital Hikes Axsome Therapeutics Price Target to $310 on Pipeline Optimism

Key Facts

1BMO Capital initiated coverage on Axsome Therapeutics with an 'Outperform' rating at a price of $221.64.
2The FDA accepted the NDA for AXS-12 in narcolepsy treatment with a PDUFA target action date of May 1, 2027.
3The company started the FOCUS-2 Phase 3 trial for solriamfetol as a potential treatment for pediatric ADHD.

Reflecting growing optimism in the biotech innovation pipeline, BMO Capital analyst Malcolm Hoffman has raised the price target for Axsome Therapeutics to $310, suggesting a potential upside of 39.87%. This positive assessment follows the FDA's acceptance of the New Drug Application for AXS-12, a treatment for narcolepsy, with a PDUFA action date set for May 1, 2027. Additionally, the company has launched the FOCUS-2 Phase 3 trial for solriamfetol as a potential treatment for pediatric ADHD, further strengthening its long-term growth prospects.

This operational momentum highlights Axsome's ability to diversify its therapeutic portfolio in a competitive market, with the company's market capitalization now reaching approximately $11.41 billion. Per market data, the stock has maintained a 52-week trading range between $96.09 and $260.19, illustrating the volatility inherent in clinical-stage developments. Analysts suggest that successful Phase 3 outcomes for solriamfetol could unlock a significant pediatric market, justifying the aggressive price target revision from institutional researchers.

Investors are closely monitoring whether the stock can break past its 52-week high of $260.19 following this upgraded guidance. Looking ahead, market participants are focused on the upcoming U.S. Consumer Price Index (CPI) data on July 14, 2026, as inflation trends often dictate risk appetite in the high-growth biotech sector. Speeches from Federal Reserve officials scheduled for the same week will also be critical in assessing the financing environment for research-heavy pharmaceutical firms.